-
Celgene Co-Founder Bags $23M for Johns Hopkins Spinout NexImmune
biospace
January 03, 2018
NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development
-
Celgene Takes a $411M Hit From Discontinuation of Crohn's Disease Trials
biospace
January 02, 2018
Celgene?announced?back in October that it was discontinuing its GED-0301 (mongersen) program for Crohn’s disease. Now Celgene has?worked?out how much that decision is costing the company—$411 million.
-
Celgene Crashed After Follicular Lymphoma Regimen Failed Phase III
biospace
December 25, 2017
Shares of?Celgene?plunged more than five points per share after the company announced Revlimid combined with?Biogen’s Rituxan?failed in a late-stage study?of previously untreated patients with follicular lymphoma.
-
Cancer Research UK agrees largest drug discovery collab to date
pharmafile
December 18, 2017
Cancer Research UK has announced that its subsidiary, Cancer Research Technology (CRT), and Celgene have agreed a drug discovery collaboration.
-
Why Pfizer Could and Should Scoop Up Celgene in 2018
biospace
December 06, 2017
Pfizer?is no stranger to taking the big gambles—note the company’s attempts to buy?AstraZeneca?in 2014 and?Allergan?in 2016
-
Celgene hikes price of Revlimid to mask poor Q3 results
pharmafile
October 30, 2017
Celgene posted its Q3 results and investors did not react well – shares plunged 16% immediately, after the biotech cut its guidance through to 2020.
-
Armo taps Celgene, GV for $67M to fuel late-phase I-O R&D
fiercebiotech
August 31, 2017
Armo will use the money to run phase 2/3 trials in renal cell and non-small cell lung cancer.
-
With IBD market set for major growth, AbbVie stands to benefit: analyst
fiercepharma
August 24, 2017
AbbVie's pipeline contains multiple prospects to treat inflammatory bowel disease.
-
Celgene opts not to acquire Sutro Biopharma for $1bn, reworks existing partnership
pharmafile
August 14, 2017
Celgene has announced that it has chosen not to scoop up Sutro Biopharma, rejecting to take advantage of an option outlined in its $1 billion partnership struck in 2014 which would allow it to acquire the US biotech.
-
Celgene drops Sutro buyout option and refocuses deal on 4 I-O programs, freeing partner to pursue ne
fiercebiotech
August 11, 2017
Celgene gained the Sutro buyout option after paying $95 million and committing to $1 billion more in 2014.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
